Satellite Bio
Overview
Satellite Bio is a biotechnology company specializing in regenerative medicine, particularly focusing on developing bioengineered tissues to repair, restore, or replace critical organ functions. Established in 2019 and headquartered in Newton, Massachusetts, Satellite Bio concentrates on liver cells through its proprietary Satellite™ Adaptive Tissue (SAT) Platform, exploring the potential of solid organ cells as medicinal agents.
Leadership and Key Personnel
- Tom Lowery, PhD: President and CEO, as well as a Board Director. Lowery initially joined Satellite Bio as the Chief Technology Officer in 2020.
- Sangeeta Bhatia, MD, PhD: Co-Founder, renowned academic affiliated with Massachusetts Institute of Technology.
- Christopher Chen, MD, PhD: Co-Founder, instrumental in technological and biological innovation.
- Arnav Chhabra, PhD: Co-Founder and VP, Head of Research, focusing on advancing the company's research initiatives.
Strategic Focus
Satellite Bio is pioneering the development of expandable, mature hepatocyte cells designed to augment or replace liver function, addressing severe and life-threatening diseases with the aim to provide long-term therapeutic solutions tailored to individual patient needs.
Technological Platform
The SAT Platform features innovations in tissue therapeutics, encompassing the expansion, seed formation, and stabilization of cells. This enables durable engraftment of cells into the human body, underpinning Satellite Bio's functional regenerative medicine solutions.
Financials and Funding
Satellite Bio has successfully raised $110 million in funding to advance its implantable tissue therapies, supported by investors such as Polaris Partners, Lightspeed Venture Partners, Section 32, and aMoon Fund.
Developments and Future Prospects
The company revealed its focus on tissue therapeutics in 2022, emerging from stealth mode. Leadership changes included the departure of former CEO Dave Lennon, PhD, and the appointment of Tom Lowery as CEO. They have also presented preclinical data at major industry conferences to signal ongoing advancement in therapeutic approaches.
Partnerships and Collaborations
Satellite Bio values strategic partnerships to facilitate the adoption and advancement of its technology, sharing a vision with its partners to leverage regenerative medicine for improved patient outcomes.
Contact Information
- Headquarters: 73D Chapel Street, Newton, MA 02458
- Website: [satellite.bio](https://satellite.bio/)
- LinkedIn: [Satellite Bio LinkedIn](https://www.linkedin.com/company/satellite-bio)
Important Links
- [Company Overview](https://satellite.bio/company)
- [Tissue Therapeutics](https://satellite.bio/tissue-therapeutics)
- [SAT Platform](https://satellite.bio/sat-platform)
- [Partnerships](https://satellite.bio/partnerships)
Satellite Bio - Competitor Profiling
Overview
Satellite Bio is focused on implantable tissue therapies within regenerative medicine, emphasizing innovation in therapeutic development. With total funding reaching $110 million and approximately 50 employees, the company is expanding its capabilities in its niche market.
Key Competitors
1. LyGenesis: Uses cell therapy for regenerating ectopic organs via lymph nodes, optimizing donor organ use.
2. Precise Bio: Known for bioprinting tissues, posing a technological challenge.
3. Lattice Medical & Avery: Focused on regenerative medicine and bioengineering.
4. Angiocrine Bioscience: Utilizes cellular therapies regenerating tissues using stem cells.
5. Humacyte: Provides competition with implantable bioengineered tissues.
6. Immunome, CRISPR Therapeutics, Slingshot Biosciences: Offer diverse therapeutic biotech solutions.
7. Ohana Biosciences and Matterworks: Competitors based on operational scale and revenue.
Industry Context
The U.S. regenerative medicine market is projected to reach USD 80.74 billion by 2033, providing both opportunities and competitive challenges as companies pursue technological advancements and market share.
This profile equips industry professionals with insight into Satellite Bio's strategic positioning, leadership, and competitive landscape within biotechnology and regenerative medicine.
